Uncategorized
Bill Gates Once Pinned Price As Hurdle To Mass EV Adoption: Now, Tesla, Lucid And Rivian Are Gearing Up To Launch Cheaper EV Models
EV makers, including Tesla and Ford, are moving towards more affordable models in hopes of increasing mass adoption of electric vehicles. read more
Top Wall Street Forecasters Revamp Compass Minerals International Price Expectations Ahead Of Q4 Earnings
Latest Ratings for CMP Date Firm Action From To Feb 2022 JP Morgan Downgrades Neutral Underweight Dec 2021 Goldman Sachs Upgrades Sell Neutral Nov 2021 Goldman Sachs Maintains Sell View More Analyst Ratings for CMP View the Latest Analyst Ratings read more
EVgo Closes $1.25 Billion Loan From Government To Expand Fast Charging Network; Stock Gains
EVgo secures a $1.25 billion loan from the U.S. Department of Energy to expand its fast charging network, aiming to triple its footprint to 10,000 stalls by 2029. read more
Elon Musk’s SpaceX Wants To Turn Its Starbase Site Into A City
Elon Musk’s rocket manufacturing company SpaceX is now looking to turn its site in Starbase, Texas, into a new city. read more
US Stocks Likely To Open Higher, Investors Eye Fed Policy Meet Next Week: Broadcom, RH, Costco In Focus
U.S. stock futures advanced on Friday in premarket after declining on Thursday. The futures of all four major indices were trading higher. read more
Elon Musk Denies xAI Licensing Sydney Sweeney’s Voice For Grok’s Advanced Mode
The post from Tech Dev Notes highlighted speculation about xAI’s intentions regarding Sweeney’s voice. read more
Taiwan Semiconductor Set to Command 67% Foundry Market Share By 2025: IDC
IDC projects Taiwan Semiconductor to see 25% revenue growth in 2025 due to AI and crypto mining, while also commanding 67% of global foundry market. read more
Broadcom Sees 4X Surge In AI Chip Sales, Fueling 44% Revenue Growth To Record $51.6 Billion In 2024: CEO Expects Momentum To Remain ‘Strong’
Broadcom Inc’s management said that they saw a four-fold increase in AI connectivity revenue driven by Tomahawk and Jericho shipments. read more
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
Editas Medicine pivots to in vivo gene editing, extends cash runway to Q2 2027, and reduces its workforce by 65%. The company reports breakthroughs in HSC and liver editing. read more
